Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Trine Lignell Guldberg"'
Autor:
Sofie Gjessing, Trine Lignell Guldberg, Torsten Risør, Regitze Gyldenholm Skals, Jette Kolding Kristensen
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Recruiting and securing primary care physician workforce has been the center of international attention for decades. In Denmark, the number of general practitioners has decreased by 8.5% since 2013. However, a rising population ag
Externí odkaz:
https://doaj.org/article/1cc772a416b74266bcca515b33251026
A national study on the inter-observer variability in the delineation of organs at risk in the brain
Autor:
Rikke Hedegaard Dahlrot, Britta Weber, Slavka Lukacova, Aida Muhic, Ihsan Bahij, Charlotte Aaquist Haslund, Petra Witt Nyström, Christian Rønn Hansen, Yasmin Lassen-Ramshad, Lone Heimann Larsen, L. Haldbo-Classen, Camilla Skinnerup Byskov, Jesper F. Kallehauge, Trine Lignell Guldberg, Ebbe Laugaard Lorenzen
Publikováno v:
Lorenzen, E L, Kallehauge, J F, Byskov, C S, Dahlrot, R H, Haslund, C A, Guldberg, T L, Lassen-Ramshad, Y, Lukacova, S, Muhic, A, Witt Nyström, P, Haldbo-Classen, L, Bahij, I, Larsen, L, Weber, B & Hansen, C R 2021, ' A national study on the inter-observer variability in the delineation of organs at risk in the brain ', Acta Oncologica, vol. 60, no. 11, pp. 1548-1554 . https://doi.org/10.1080/0284186X.2021.1975813
BACKGROUND: The Danish Neuro Oncology Group (DNOG) has established national consensus guidelines for the delineation of organs at risk (OAR) structures based on published literature. This study was conducted to finalise these guidelines and evaluate
Autor:
Ihsan Bahij, Rikke Hedegaard Dahlrot, Slavka Lukacova, Yasmin Lassen-Ramshad, L. Haldbo-Classen, Aida Muhic, Petra Witt Nyström, C. Rønn Hansen, Lars Allan Larsen, Camilla Skinnerup Byskov, Charlotte Aaquist Haslund, Christian Rønn Hansen, Britta Weber, Trine Lignell Guldberg, Ebbe Laugaard Lorenzen, Jesper F. Kallehauge
Publikováno v:
Radiotherapy and Oncology. 161:S473-S475
Autor:
A. R. Korshøj, Frantz Rom Poulsen, Nikola Mikic, Eric T. Wong, Jane Skjøth-Rasmussen, K. B. Kristoffersen, Jens Christian Sørensen, Trine Lignell Guldberg, Susanne Møller, Rikke Hedegaard Dahlrot, R. J. Laursen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Mikic, N, Poulsen, F R, Kristoffersen, K B, Laursen, R J, Guldberg, T L, Skjøth-Rasmussen, J, Wong, E T, Møller, S, Dahlrot, R H, Sørensen, J C H & Korshøj, A R 2021, ' Study protocol for OptimalTTF-2 : enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial ', BMC Cancer, vol. 21, 1010 . https://doi.org/10.1186/s12885-021-08709-4
Mikic, N, Poulsen, F R, Kristoffersen, K B, Laursen, R J, Guldberg, T L, Skjøth-Rasmussen, J, Wong, E T, Møller, S, Dahlrot, R H, Sørensen, J C H & Korshøj, A R 2021, ' Study protocol for OptimalTTF-2 : enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial ', BMC Cancer, vol. 21, no. 1, 1010 . https://doi.org/10.1186/s12885-021-08709-4
BMC Cancer
Mikic, N, Poulsen, F R, Kristoffersen, K B, Laursen, R J, Guldberg, T L, Skjøth-Rasmussen, J, Wong, E T, Møller, S, Dahlrot, R H, Sørensen, J C H & Korshøj, A R 2021, ' Study protocol for OptimalTTF-2 : enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial ', BMC Cancer, vol. 21, 1010 . https://doi.org/10.1186/s12885-021-08709-4
Mikic, N, Poulsen, F R, Kristoffersen, K B, Laursen, R J, Guldberg, T L, Skjøth-Rasmussen, J, Wong, E T, Møller, S, Dahlrot, R H, Sørensen, J C H & Korshøj, A R 2021, ' Study protocol for OptimalTTF-2 : enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial ', BMC Cancer, vol. 21, no. 1, 1010 . https://doi.org/10.1186/s12885-021-08709-4
BMC Cancer
Background OptimalTTF-2 is a randomized, comparative, multi-center, investigator-initiated, interventional study aiming to test skull remodeling surgery in combination with Tumor Treating Fields therapy (TTFields) and best physicians choice medical o
Autor:
Søren Ole Stigaard Cortnum, Mette Haldrup Jensen, Nikola Mikic, Jens Christian Sørensen, Trine Lignell Guldberg, Yasmin Lassen-Ramshad, Anders Rosendal Korshoej, Kåre Eg Severinsen, Christian Rahbek, Slavka Lukacova, Gorm von Oettingen
Publikováno v:
Neuro-oncology Advances
Korshoej, A R, Lukacova, S, Lassen-Ramshad, Y, Rahbek, C, Severinsen, K E, Guldberg, T L, Mikic, N, Jensen, M H, Cortnum, S O S, von Oettingen, G & Sørensen, J C H 2020, ' OptimalTTF-1 : Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma ', Neuro-oncology advances, vol. 2, no. 1, vdaa121 . https://doi.org/10.1093/noajnl/vdaa121
Korshoej, A R, Lukacova, S, Lassen-Ramshad, Y, Rahbek, C, Severinsen, K E, Guldberg, T L, Mikic, N, Jensen, M H, Cortnum, S O S, von Oettingen, G & Sørensen, J C H 2020, ' OptimalTTF-1 : Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma ', Neuro-oncology advances, vol. 2, no. 1, vdaa121 . https://doi.org/10.1093/noajnl/vdaa121
Background Preclinical studies suggest that skull remodeling surgery (SR-surgery) increases the dose of tumor treating fields (TTFields) in glioblastoma (GBM) and prevents wasteful current shunting through the skin. SR-surgery introduces minor skull
Autor:
Trine Lignell Guldberg, Morten Høyer, Aida Muhic, A K Trip, V K Veluppillai, Slavka Lukacova, Rikke Hedegaard Dahlrot
Publikováno v:
Trip, A K, Veluppillai, V K, Dahlrot, R H, Lignell Guldberg, T, Muhic, A & Lukacova, S 2021, ' P14.69 Trends in postoperative chemoradiotherapy for Glioblastoma patients : a Danish cohort study ', Neuro-Oncology, vol. 23, no. Suppl. 2, pp. ii51 . https://doi.org/10.1093/neuonc/noab180.176
BACKGROUND Postoperative chemoradiotherapy (CRT), using conventional radiotherapy (convRT), has a key role in the treatment of glioblastoma (GBM) supported by level 1A evidence. In the past decade, evidence supporting hypofractionated radiotherapy (H
Autor:
Trine Lignell Guldberg, Jesper F. Kallehauge, Slavka Lukacova, Morten B. Jensen, Anja Harbøll
Publikováno v:
Jensen, M B, Guldberg, T L, Harbøll, A, Lukacova, S & Kallehauge, J F 2017, ' Diffusion tensor magnetic resonance imaging driven growth modeling for radiotherapy target definition in glioblastoma ', Acta Oncologica, vol. 56, no. 11, pp. 1639-1643 . https://doi.org/10.1080/0284186X.2017.1374559
BACKGROUND:The clinical target volume (CTV) in radiotherapy is routinely based on gadolinium contrast enhanced T1 weighted (T1w + Gd) and T2 weighted fluid attenuated inversion recovery (T2w FLAIR) magnetic resonance imaging (MRI) sequences which hav
Publikováno v:
Guldberg, T L, Christensen, S, Zachariae, R & Jensen, A B 2017, ' Prognostic factors in early breast cancer associated with body mass index, physical functioning, physical activity, and comorbidity : data from a nationwide Danish cohort ', Breast Cancer Research and Treatment, vol. 162, no. 1, pp. 159-167 . https://doi.org/10.1007/s10549-016-4099-y
PURPOSE: To explore the associations between lifestyle-related factors and tumor-related prognostic factors in women treated for primary breast cancer, and to detect possible differences between the associations in pre- and postmenopausal women.METHO
Autor:
Slavka Lukacova, Frederik Boe Hansen, Nikola Mikic, Christian Rahbek, Trine Lignell Guldberg, Yasmin Ramshad-Lassen, Søren Ole Stigaard Cortnum, Gorm von Oettingen, Kåre Eg Severinsen, Axel Thielscher, Jens Christian Sørensen, Anders Rosendal Korshøj
Publikováno v:
Korshoej, A R, Mikic, N, Lukácová, S, Sørensen, J C H, Lundgaard Hansen, F, Thielscher, A, Cortnum, S, Guldberg, T L, Lassen-Ramshad, Y, Rahbek, C, Severinsen, K & Oettingen, G V 2019, ' SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH ', Neuro-Oncology, bind 21, nr. Supplement 6, vi239–vi240 . https://doi.org/10.1093/neuonc/noz175.1002
Neuro Oncol
Neuro Oncol
BACKGROUND OptimalTTF-1(open-label phase-1) combines Tumor Treating Fields(TTFields) treatment with targeted skull-remodeling surgery(SR-surgery) aiming to enhance the electric field strength in the tumor(NCT02893137). SR-surgery aims to reduce the e
Autor:
Anders Rosendal Korshøj, Slavka Lukacova, Yasmin Ramshad-Lassen, G von Oettingen, Jens Christian Sørensen, Frederik Lundgaard Hansen, Christian Rahbek, Søren Ole Stigaard Cortnum, Trine Lignell Guldberg, Kåre Eg Severinsen, Axel Thielscher, Nikola Mikic
Publikováno v:
Korshoej, A R, Mikic, N, Lukacova, S, Sørensen, J C H, Lundgaard Hansen, F, Thielscher, A, Cortnum, S O S, Guldberg, T L, Lassen-Ramshad, Y, Rahbek, C, Severinsen, K E & Oettingen, G V 2019, ' P05.03 OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity ', Neuro-Oncology, bind 41, nr. Supplement 3, s. iii34 . https://doi.org/10.1093/neuonc/noz126.117
Neuro Oncol
Neuro Oncol
BACKGROUND OptimalTTF-1 is an open-label phase-1 study on the combination of Tumor Treating Fields (TTFields) treatment together with targeted skull remodeling surgery aiming to enhance the electric field intensity in the brain (NCT02893137). Skull-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdd08eeb69e073f28e2f4327ec541e47
https://pure.au.dk/portal/da/publications/p0503-optimalttf1-final-results-of-a-phase-1-study-at-first-glioblastoma-recurrence-examining-targeted-craniotomy-to-enhance-tumor-treating-fields-intensity(29a7913e-c9f9-46f5-80db-e12ffb1dc8a0).html
https://pure.au.dk/portal/da/publications/p0503-optimalttf1-final-results-of-a-phase-1-study-at-first-glioblastoma-recurrence-examining-targeted-craniotomy-to-enhance-tumor-treating-fields-intensity(29a7913e-c9f9-46f5-80db-e12ffb1dc8a0).html